Immuno-Oncology (I-O) Focus

Chemotherapy: the backbone of lymphoma treatment

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

The role of MRD in multiple myeloma

VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.

Novel agents in MDS

VJHemOnc is pleased to bring you a feature exploring the latest advances and developments in novel agents for MDS, with…

MRD as a clinical and regulatory endpoint for AML

VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…

ASH late-breaking abstract rundown

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

ASH press briefing rundown: optimizing pediatric care

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

ASH press briefing rundown: new drugs and targets

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

Biological therapy in NHL: treating with CAR-T versus BiTEs

VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…

Teclistamab receives EMA approval for adult patients with relapsed/refractory (R/R) multiple myeloma

On August 24 2022, the European Medicines Agency (EMA) approved the use of teclistamab for the treatment of patients with…

Betibeglogene autotemcel receives FDA approval for patients with transfusion-dependent β-thalassemia

On August 17 2022, the US Food and Drug Administration (FDA) approved the first cell-based gene therapy, betibeglogene autotemcel (beti-cel),…

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

Highlights in myeloid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…

Approval of axi-cel in second-line for R/R LBCL & label update

Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…

Amyloidosis: current challenges and future outlooks

VJHemOnc is excited to bring you a feature covering current challenges and future outlooks in amyloidosis.

Genomic testing and clinical decision making in CLL

Learn about the importance of performing genomic testing in CLL and how this impacts diagnosis, prognosis and treatment decisions.

Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…

features: Immuno-Oncology

Chemotherapy: the backbone of lymphoma treatment

The role of MRD in multiple myeloma

Novel agents in MDS

MRD as a clinical and regulatory endpoint for AML

ASH late-breaking abstract rundown

ASH press briefing rundown: optimizing pediatric care

ASH press briefing rundown: new drugs and targets

Biological therapy in NHL: treating with CAR-T versus BiTEs

Teclistamab receives EMA approval for adult patients with relapsed/refractory (R/R) multiple myeloma

Betibeglogene autotemcel receives FDA approval for patients with transfusion-dependent β-thalassemia

Highlights in lymphoid malignancies from EHA 2022

Highlights in myeloid malignancies from EHA 2022

Approval of axi-cel in second-line for R/R LBCL & label update

Amyloidosis: current challenges and future outlooks

Genomic testing and clinical decision making in CLL

Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma

Sign-up for our Newsletter!